# Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

> **NCT04892849** · — · RECRUITING · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 200 (estimated)

## Conditions studied

- HNSCC
- NSCLC
- Esophageal Cancer
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
- Small Cell Bronchial Carcinomas

## Interventions

- **OTHER:** Conventional Therapy acc. to prevailing clincal approved schemes

## Key facts

- **NCT ID:** NCT04892849
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2028-05-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892849, "Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04892849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*